13F Insight
DOSSIER · 13F-HR · Q4 2025

BVF INC/IL

$3.0B in tracked AUM across 41 positions as of Q4 2025.

BI
CIK 0001056807 · last filed Dec 31, 2025
Total AUM
$3.0B
as of Q4 2025
Holdings
41
—
positions
Whale Score
68
68
tracked
Activity
—
no data
changes this Q
AI Analysis · Q4 2025
Comprehensive Analysis of BVF INC/IL SEC 13F Filing (Q3 2025)
1. Portfolio Overview

BVF INC/IL (managed by Perceptive Advisors, a biotech-focused investment firm) has reported a significant contraction in portfolio value for the quarter ended September 30, 2025. The total assets under management (AUM) dropped by 50.8%, decreasing from $2.80 billion in the previous quarter to $1.38 billion. This reduction is not solely attributable to market performance but is largely driven by active capi...

The portfolio remains highly concentrated, holding 34 positions. The strategy is characterized by a high-conviction approach, with the top 10 holdings accounting for approximately 67% of the total portfolio value. The firm maintains a focused exposure on the biotechnology and healthcare sectors, utilizing a strategy that likely involves identifying undervalued or high-growth potential clinical-stage companies.

2. Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q4 2025. Methodology

Quarter at a glance — Q4 2025

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q4 2025.

#HoldingValueSharesWeight
01
KYMR
KYMERA THERAPEUTICS INC
$428M5.5M14.4%02
RVMD
REVOLUTION MEDICINES INC
$267M3.4M9.0%03
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
$260M19.8M8.8%04
GPCR
STRUCTURE THERAPEUTICS INC
$242M3.5M8.1%05
OLMA
OLEMA PHARMACEUTICALS INC
$132M5.3M4.5%06
MIRM
MIRUM PHARMACEUTICALS INC
$118M1.5M4.0%07
G3855L106
GH RESEARCH PLC
$112M8.8M3.8%08
XNCR
XENCOR INC
$109M7.1M3.7%09
ZYME
ZYMEWORKS INC
$104M3.9M3.5%10
PVLA
PALVELLA THERAPEUTICS INC NE
$92M879K3.1%

Filing history

2025Q4Dec 31
$3.0B▲ 115.6%
41 positionsView →2025Q3Sep 30
$1.4B▼ 50.8%
34 positionsView →2025Q2Jun 30
$2.8B▲ 52.7%
44 positionsLocked2025Q1Mar 31
$1.8B▼ 37.9%
38 positionsLocked2024Q4Dec 31
$3.0B▼ 13.7%
53 positionsLocked2024Q3Sep 30
$3.4B▼ 4.2%
55 positionsLocked2024Q2Jun 30
$3.6B▼ 1.9%
60 positionsLocked2024Q1Mar 31
$3.6B▼ 9.0%
62 positionsLocked2023Q4Dec 31
$4.0B▲ 7.7%
70 positionsLocked2023Q3Sep 30
$3.7B▲ 3.4%
69 positionsLocked2023Q2Jun 30
$3.6B▲ 31.2%
67 positionsLocked2023Q1Mar 31
$2.7B▲ 15.5%
72 positionsLocked
Showing 12 of 78